AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7506176 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (50mg granules twice daily)
Number of subjects: 70
Study 7506176 — intervention group
Group type: COMPARATOR
Intervention: lysine-aspirin (360mg granules twice daily)
Number of subjects: 70
Study 3566994 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 50
Study 3566994 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 50
Study 31755374 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential Learning (DL)
Number of subjects: 32
Study 31755374 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual Interference (CI)
Number of subjects: 32
Study 30004565 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional exercises of passive and autonomic activities
Number of subjects: 92
Study 27852283 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 25
Study 27852283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24114421 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 50
Study 24114421 — intervention group
Group type: COMPARATOR
Intervention: Intense pulsed light therapy (IPL)
Number of subjects: 50
Study 22819275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean children
Number of subjects: 162
Study 22819275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study 20546545 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football (FG)
Number of subjects: 28
Study 20546545 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (RG)
Number of subjects: 28
Study 20546545 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 18465391 — intervention group
Group type: EXPERIMENTAL
Intervention: BB&B programme
Number of subjects: 162
Study 18465391 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BB&B programme)
Number of subjects: 162
Study 15823625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor moexipril added to combination therapy
Number of subjects: 420
Study 12094189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 234
Study 12094189 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem CD
Number of subjects: 234
Study 10511936 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (Allergan SI‐40NB)
Number of subjects: 62
Study 10511936 — intervention group
Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) intraocular lenses (Pharmacia 812 C)
Number of subjects: 62
Study 7738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial fat mass and fat mass slope plus either vitamin A, carotene, fiber, magnesium, or phosphorus
Number of subjects: 66
Study 7738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass slope plus sodium
Number of subjects: 66
Study 7738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 66
Study 7738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial fat mass
Number of subjects: 66
Study 7738683 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 66
Study 2045727 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (three levels of dosage)
Number of subjects: 55
Study 2045727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6768443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa weekly for one year (N = 90)
Number of subjects: 90
Study 6768443 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control group, N = 77)
Number of subjects: 90
Study 6768443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa treatment in negative node patients less than 55 years old
Number of subjects: 90
Study 31591940 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprenone 150 mg/day
Number of subjects: 130
Study 31591940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 29351138 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 70
Study 29351138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27835981 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Shift video game intervention
Number of subjects: 366
Study 27835981 — intervention group
Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 366
Study 24858141 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of vitamin D
Number of subjects: 213
Study 24858141 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D
Number of subjects: 213
Study 24858141 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin D
Number of subjects: 213
Study 24858141 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D
Number of subjects: 213
Study 24858141 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 213
Study 22622598 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 504
Study 19638336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.001% bFGF
Number of subjects: 150
Study 19638336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% bFGF
Number of subjects: 150
Study 19638336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 17889680 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow injection (2.0 mL lidocaine with 1:80,000 epinephrine over 60 seconds)
Number of subjects: 38
Study 17889680 — intervention group
Group type: COMPARATOR
Intervention: Rapid injection (2.0 mL lidocaine with 1:80,000 epinephrine over 15 seconds)
Number of subjects: 38
Study 15547121 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (prefabricated)
Number of subjects: 0
Study 15547121 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses (customized)
Number of subjects: 0
Study 15547121 — intervention group
Group type: COMPARATOR
Intervention: Foot orthoses (prefabricated or customized)
Number of subjects: 0
Study 11732862 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 and IL-15 levels in patients' serum
Number of subjects: 35
Study 11732862 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble CD26 levels in patients' serum
Number of subjects: 35
Study 11732862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine deaminase levels in patients' serum
Number of subjects: 35
Study 9205762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 400 mg daily
Number of subjects: 110
Study 9205762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 600 mg daily
Number of subjects: 110
Study 9205762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg daily
Number of subjects: 110
Study 9205762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 200 mg daily
Number of subjects: 110
Study 9205762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7963150 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril once daily)
Number of subjects: 251
Study 7963150 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 251
Study 7963150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 3598772 — intervention group
Group type: COMPARATOR
Intervention: 38 kcal/kg/d nonprotein energy (Group 1)
Number of subjects: 19
Study 3598772 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 kcal/kg/d nonprotein energy (Group 2)
Number of subjects: 19
Study 3598772 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 kcal/kg/d nonprotein energy plus 1 to 2 g/kg/d crystalline amino acids (Group 3)
Number of subjects: 19
Study 3598772 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 19
Study 28988339 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180
Study 28988339 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PEP)
Number of subjects: 180
Study 26764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi)
Number of subjects: 180
Study 26764260 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 180
Study 24655439 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation programs for chronic diseases
Number of subjects: 0
Study 24655439 — intervention group
Group type: COMPARATOR
Intervention: Qualitative analysis in Norway
Number of subjects: 0
Study 22542362 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab therapy
Number of subjects: 11
Study 20056719 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 171
Study 20056719 — intervention group
Group type: COMPARATOR
Intervention: Self-Management (SM)
Number of subjects: 171
Study 18317625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus orlistat 120 mg three times daily
Number of subjects: 30
Study 18317625 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet alone
Number of subjects: 30
Study 16046191 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GBP)
Number of subjects: 1156
Study 16046191 — intervention group
Group type: COMPARATOR
Intervention: Control group (GBP seeking individuals denied surgery)
Number of subjects: 1156
Study 16046191 — intervention group
Group type: COMPARATOR
Intervention: Control group (severely obese not seeking GBP)
Number of subjects: 1156
Study 11945148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg/day)
Number of subjects: 496
Study 11945148 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 496
Study 10333912 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus repaglinide
Number of subjects: 83
Study 10333912 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide monotherapy
Number of subjects: 83
Study 10333912 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 83
Study 10333912 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (combined therapy)
Number of subjects: 83
Study 10333912 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide (monotherapy)
Number of subjects: 83
Study 10333912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (metformin and repaglinide)
Number of subjects: 83
Study 7793116 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous s.c. infusion of AVP (7.5 micrograms/d) for one week
Number of subjects: 5
Study 7793116 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl-solution (placebo)
Number of subjects: 5
Study 2025476 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol anaesthesia (group II, n = 15)
Number of subjects: 30
Study 2025476 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil-nitrous oxide anaesthesia (group I, n = 15)
Number of subjects: 30
Study 2025476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6 mg kg‐1 h‐1 after 90 min of nitrous oxide 66% in oxygen
Number of subjects: 30
Study 7344590 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 400mg or more daily (once daily dosing)
Number of subjects: 0
Study 7344590 — intervention group
Group type: COMPARATOR
Intervention: Acebutolol 400mg or more daily (twice daily dosing)
Number of subjects: 0
Study 30726107 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Running (HICR)
Number of subjects: 20
Study 30726107 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Running (MICR)
Number of subjects: 20
Study 30726107 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 20
Study 28241159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (LT)
Number of subjects: 31
Study 28241159 — intervention group
Group type: COMPARATOR
Intervention: Dim-Red Light Therapy (Control)
Number of subjects: 31
Study 25399699 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of manualized training in dialogic book-sharing
Number of subjects: 91
Study 25399699 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 91
Study 24368615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-led walking (weeks 1 to 10)
Number of subjects: 75
Study 24368615 — intervention group
Group type: COMPARATOR
Intervention: Independent walking (weeks 11 to 16)
Number of subjects: 75
Study 24368615 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 75
Study 22584195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat exposure
Number of subjects: 299
Study 22584195 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare exposure
Number of subjects: 299
Study 22584195 — intervention group
Group type: COMPARATOR
Intervention: Maternal asthma
Number of subjects: 299
Study 22584195 — intervention group
Group type: COMPARATOR
Intervention: Baseline body mass index
Number of subjects: 299
Study 22584195 — intervention group
Group type: COMPARATOR
Intervention: Specific immunoglobulin E to house-dust mix at 3 years
Number of subjects: 299
Study 22584195 — intervention group
Group type: COMPARATOR
Intervention: Dog, mouse, rat, and cockroach exposures
Number of subjects: 299
Study 19350472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 360
Study 19350472 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental add-on therapy with D-Cycloserine
Number of subjects: 360
Study 17306703 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (0.75 microg/kg every 2 weeks for 26 weeks)
Number of subjects: 41
Study 17306703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 14985175 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine intake (300-350 ml, approximately two glasses)
Number of subjects: 24
Study 14985175 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine intake (300-350 ml, approximately two glasses)
Number of subjects: 24
Study 14985175 — intervention group
Group type: COMPARATOR
Intervention: Control (no wine consumption)
Number of subjects: 24
Study 11152852 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) plus estradiol
Number of subjects: 0
Study 11152852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9885068 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginary enactment
Number of subjects: 4
Study 9885068 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual construction
Number of subjects: 4
Study 9885068 — intervention group
Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 4
Study 9885068 — intervention group
Group type: COMPARATOR
Intervention: Imagining construction
Number of subjects: 4
Study 7730878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF)
Number of subjects: 201
Study 7730878 — intervention group
Group type: COMPARATOR
Intervention: Normal western diet (ND)
Number of subjects: 201
Study 7730878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF) in women
Number of subjects: 201
Study 7730878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF) in men
Number of subjects: 201
Study 3898645 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological biobehavioral treatment program
Number of subjects: 30
Study 3898645 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 30
Study 3898645 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study 31985531 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum transferrin
Number of subjects: 828
Study 31985531 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores (model of end-stage liver disease, Glasgow alcoholic hepatitis score, discriminant function)
Number of subjects: 828
Study 31985531 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 828
Study 30350844 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol + aspirin
Number of subjects: 142
Study 30350844 — intervention group
Group type: COMPARATOR
Intervention: Placebo + aspirin
Number of subjects: 142
Study 27144494 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a 10-week randomized controlled trial of atomoxetine
Number of subjects: 14
Study 27144494 — intervention group
Group type: COMPARATOR
Intervention: 90% reliable change indices (RCIs) based on healthy adults
Number of subjects: 14
Study 27144494 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% reliable change indices (RCIs) based on PD‐MCI sample
Number of subjects: 14
Study 27144494 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function tests
Number of subjects: 14
Study 24667714 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetPrint
Number of subjects: 800
Study 24667714 — intervention group
Group type: COMPARATOR
Intervention: Local assessment
Number of subjects: 800
Study 22608359 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 60 mg twice daily
Number of subjects: 76
Study 22608359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 20492039 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor gardening programme (8 weeks)
Number of subjects: 53
Study 20492039 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 53
Study 18640458 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792 (Aβ42 immunisation)
Number of subjects: 80
Study 18640458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17492558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone tunnel fixation
Number of subjects: 48
Study 17492558 — intervention group
Group type: COMPARATOR
Intervention: Suture anchor
Number of subjects: 48
Study 15319673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg twice daily) + optimized background regimen
Number of subjects: 995
Study 15319673 — intervention group
Group type: COMPARATOR
Intervention: Optimized background regimen alone
Number of subjects: 995
Study 11044234 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg daily
Number of subjects: 12
Study 11044234 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 9285079 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 14
Study 9285079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1362671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen injector (Human NPH insulin in penfills)
Number of subjects: 18
Study 1362671 — intervention group
Group type: COMPARATOR
Intervention: Syringe (Human NPH insulin in vials)
Number of subjects: 18
Study 1362671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen injector
Number of subjects: 18
Study 1362671 — intervention group
Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 18
Study 1362671 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 18
Study 3516754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream
Number of subjects: 30
Study 3516754 — intervention group
Group type: COMPARATOR
Intervention: Desonide (Apolar) 0.1% ointment
Number of subjects: 30
Study 30865051 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing arm of FTC/TDF-based PrEP
Number of subjects: 176
Study 30865051 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 176
Study 28343582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application (+8°C) for 20 minutes
Number of subjects: 18
Study 28343582 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral application (+32°C) for 20 minutes
Number of subjects: 18
Study 28343582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application (+8°C)
Number of subjects: 18
Study 28343582 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral application (+32°C)
Number of subjects: 18
Study 26510664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI (CBM) - 9 tablets orally once daily
Number of subjects: 17
Study 26510664 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 9 tablets orally once daily
Number of subjects: 17
Study 24613524 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccination (PPS)
Number of subjects: 230
Study 24613524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal carriage with 19F or 23F prior to PPS immunization
Number of subjects: 230
Study 22009018 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated time limit scale (ETL) for regulating exercise intensity
Number of subjects: 36
Study 19746336 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (direct transfer to ward after assessment using the White and Song scoring system)
Number of subjects: 157
Study 19746336 — intervention group
Group type: COMPARATOR
Intervention: Group B (transfer to PACU before ward)
Number of subjects: 157
Study 17518954 — intervention group
Group type: EXPERIMENTAL
Intervention: First premolar/canine-guided occlusion denture (CGD)
Number of subjects: 20
Study 17518954 — intervention group
Group type: COMPARATOR
Intervention: Lingualised occlusion denture (LOD)
Number of subjects: 20
Study 15159414 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus mitoxantrone (FM)
Number of subjects: 140
Study 15159414 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 140
Study 11472321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC)
Number of subjects: 120
Study 11472321 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC)
Number of subjects: 120
Study 9751449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol alone
Number of subjects: 18
Study 9751449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol plus desogestrel
Number of subjects: 18
Study 9751449 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate
Number of subjects: 18